From: A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
Adverse event
n (%)
Headache
28 (11.4)
Hallucination, auditory
26 (10.6)
Insomnia
Constipation
23 (9.4)
Akathisia
14 (5.7)
Extrapyramidal disorder
13 (5.3)
Upper respiratory tract infection
Tremor